NDAORALTABLET
Approved
Oct 2023
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
5/8 — Partial
ZITUVIO (sitagliptin) by Biocon is dipeptidyl peptidase 4 inhibitors [moa]. Approved for type 2 diabetes mellitus, diabetes. First approved in 2023.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZITUVIO (sitagliptin) is an oral DPP-4 inhibitor tablet approved by Biocon in October 2023 for Type 2 Diabetes Mellitus. It works by inhibiting dipeptidyl peptidase-4, an enzyme that degrades incretin hormones, thereby increasing insulin secretion in response to glucose. This mechanism helps lower blood glucose levels in patients with inadequate glycemic control.
Growth8.8 years to LOE
Recently approved product in growth phase with 8.9 years of patent protection, offering opportunity to build brand presence in a competitive diabetes market with potential for team expansion.
Mechanism of Action
Dipeptidyl Peptidase 4 Inhibitors
Pharmacologic Class:
Dipeptidyl Peptidase 4 Inhibitor
Indications (2)
Clinical Trials (20)
Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Relative to Originator
Started Jun 2024
34 enrolled
Healthy Subjects
Sitagliptin and Metformin Hydrochloride Tablets 50 mg/1000 mg Relative to Originator
Started Apr 2024
34 enrolled
Healthy Subjects
Semaglutide vs Sitagliptin
Started Oct 2022
58 enrolled
Liver Transplant; ComplicationsDiabetes MellitusNASH - Nonalcoholic Steatohepatitis+1 more
Phase 1 Bioequivalence Study of Dapagliflozin/Sitagliptin FDC vs Loose Combination of Single Components
Started Mar 2022
46 enrolled
Healthy Volunteers (Intended Indication: Type 2 Diabetes Mellitus)
A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes
Started Jul 2019
1,441 enrolled
Diabetes Mellitus, Type 2
Worked on ZITUVIO at Biocon? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.